306 related articles for article (PubMed ID: 28117884)
1. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
Weisdorf DJ; Millard HR; Horowitz MM; Hyare PS; Champlin R; Ho V; Mielcarek M; Rezvani A; Stockerl-Goldstein K; Khoury HJ; De Lima M; Saber W; Sandmaier B; Zhang MJ; Eapen M
Cancer; 2017 Jun; 123(11):2025-2034. PubMed ID: 28117884
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
3. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
5. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Bone Marrow Transplant; 2015 Nov; 50(11):1405-10. PubMed ID: 26168067
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Heinicke T; Krahl R; Kahl C; Cross M; Scholl S; Wolf HH; Hähling D; Hegenbart U; Peter N; Schulze A; Florschütz A; Schmidt V; Reifenrath K; Zojer N; Junghanss C; Sayer HG; Maschmeyer G; Späth C; Hochhaus A; Fischer T; Al-Ali HK; Niederwieser D
Ann Hematol; 2021 Sep; 100(9):2387-2398. PubMed ID: 34232360
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
Ustun C; Giannotti F; Zhang MJ; Wang HL; Brunstein C; Labopin M; Rocha V; de Lima M; Baron F; Sandmaier BM; Eapen M; Gluckman E; Nagler A; Weisdorf DJ; Ruggeri A
Leukemia; 2017 Jun; 31(6):1408-1414. PubMed ID: 28119528
[TBL] [Abstract][Full Text] [Related]
9. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
11. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
12. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
[TBL] [Abstract][Full Text] [Related]
13. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
[TBL] [Abstract][Full Text] [Related]
14. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.
Holtick U; Shimabukuro-Vornhagen A; Chakupurakal G; Theurich S; Leitzke S; Burst A; Hallek M; von Bergwelt-Baildon M; Scheid C; Chemnitz JM
Eur J Haematol; 2016 May; 96(5):475-82. PubMed ID: 26132980
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
16. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.
Yanada M; Yamasaki S; Kondo T; Kawata T; Harada K; Uchida N; Doki N; Yoshihara S; Katayama Y; Eto T; Tanaka M; Takada S; Kawakita T; Nishida T; Ota S; Serizawa K; Onizuka M; Kanda Y; Fukuda T; Atsuta Y; Konuma T
Leukemia; 2024 Mar; 38(3):513-520. PubMed ID: 38129514
[TBL] [Abstract][Full Text] [Related]
18. The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
Yanada M; Konuma T; Yamasaki S; Mizuno S; Hirabayashi S; Nishiwaki S; Uchida N; Doki N; Tanaka M; Ozawa Y; Sawa M; Eto T; Kawakita T; Ota S; Fukuda T; Onizuka M; Kimura T; Atsuta Y; Kako S; Yano S
Ann Hematol; 2021 Dec; 100(12):3017-3027. PubMed ID: 34477952
[TBL] [Abstract][Full Text] [Related]
19. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission.
Lee YJ; Baek DW; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Kim HJ; Ham JY; Suh JS; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e529-e535. PubMed ID: 30268640
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M; Schliemann C; Schetelig J; Röllig C; Kramer M; Glass B; Platzbecker U; Burchert A; Hänel M; Müller LP; Klein S; Bug G; Beelen D; Rösler W; Schäfer-Eckart K; Schmid C; Jost E; Lenz G; Tischer J; Spiekermann K; Pfirrmann M; Serve H; Stölzel F; Alakel N; Middeke JM; Thiede C; Ehninger G; Berdel WE; Stelljes M
JAMA Oncol; 2023 Apr; 9(4):519-526. PubMed ID: 36757706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
